

## Invitation to presentation of Egetis' fourth quarter and year-end 2025 report on February 26, 2026

**Stockholm, Sweden, February 19, 2026.** Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX) today announced that it will publish its fourth quarter and year-end 2025 report on Thursday, February 26, 2026, at 07:00 am CET. Egetis will also host a conference call the same day at 10:00 am CET to discuss the fourth quarter and year-end 2025 financial results and give a corporate update.

If you wish to participate via webcast, please use the link below. You can ask written questions via the webcast.

<https://egetis.events.inderes.com/q4-report-2025>

If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://events.inderes.com/egetis/q4-report-2025/dial-in>

The conference call will be made available on the Company's website after the call.

### For further information, please contact

---

Nicklas Westerholm, CEO

[nicklas.westerholm@egetis.com](mailto:nicklas.westerholm@egetis.com)

+46 (0) 733 542 062

Yilmaz Mahshid, CFO

[yilmaz.mahshid@egetis.com](mailto:yilmaz.mahshid@egetis.com)

+46 (0) 722 316 800

Karl Hård, Head of Investor Relations & Business Development

[karl.hard@egetis.com](mailto:karl.hard@egetis.com)

+46 (0) 733 011 944

## About Egetis Therapeutics

---

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company's lead drug candidate Emcitate® (tiratricol) is developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In February 2025 the European Commission approved Emcitate® as the first and only treatment for MCT8 deficiency in EU. Egetis initiated the launch of Emcitate® in Germany on May 1, 2025. Emcitate® (tiratricol) is not approved in the USA.

The Company completed a rolling New Drug Application (NDA) for Emcitate® (tiratricol) in the USA on January 29, 2026. The FDA is expected to confirm within 60 days that the NDA submission is complete. As a designated Fast Track and Breakthrough Therapy, Egetis has requested Priority Review, and if granted, the FDA review should be completed within six months following the 60-day filing review period.

Based on feedback from the FDA, the NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency will be based on currently available clinical data from Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study and the US Expanded Access Program.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA, which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval.

The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for Aladote® has been parked. Aladote® has been granted ODD in the US and in the EU.

Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX).

For more information, see [www.egetis.com](http://www.egetis.com)

## Attachments

---

[Invitation to presentation of Egetis' fourth quarter and year-end 2025 report on February 26, 2026](#)